BBOT · BridgeBio Oncology Therapeutics, Inc.
$9.23
-0.04 (-0.38%)
At close · Aug 27
Market Cap
$742.41M
Shares
80.17M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Eli Wallace | Former President and Chief Executive Officer | $11,489,545 |
| Uneek Mehra | M.B.A. Former Chief Financial Officer | $4,555,625 |
| Yong Ben | M.D., M.B.A.^^ Chief Medical and Development Officer | $3,227,364 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Eli Wallace | Former President and Chief Executive Officer | $4,463,320 |
| Yong Ben | M.D., M.B.A.^^ Chief Medical and Development Officer | $1,455,587 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Frank P. McCormick, Ph.D., F.R.S., D. Sc. | Class I director | Appointed | 2026-06-22 |
| Peter Lebowitz, M.D., Ph.D. | Class I director | Appointed | 2026-06-22 |
| Pedro J. Beltran, Ph.D. | President and Chief Executive Officer | Appointed | 2026-04-29 |
| Pedro J. Beltran, Ph.D. | member of the Company's Board of Directors and as a Class III director | Appointed | 2026-04-29 |
| Eli Wallace, Ph.D. | member of the Company's Board of Directors and as a Class III director | Resigned | 2026-04-29 |
| Idan Elmelech | Chief Operating Officer | Appointed | 2026-04-23 |
| Eli Wallace, Ph.D. | member of the Board and Class III director | Resigned | 2026-04-23 |
| Pedro Beltran, Ph.D. | Class III director | Appointed | 2026-04-23 |
| Pedro Beltran, Ph.D. | President and Chief Executive Officer | Appointed | 2026-04-23 |
| Peter Lebowitz, M.D., Ph.D. | Class I director | Appointed | 2026-03-26 |
| Pedro Beltran | Chief Scientific Officer | Appointed | 2025-08-13 |
| Yong Ben | Chief Medical and Development Officer | Appointed | 2025-08-13 |
| Eli Wallace | Chief Executive Officer | Appointed | 2025-08-13 |
| Jake Bauer | member of the PubCo Board | Appointed | 2025-08-13 |
| Michelle Doig | member of the PubCo Board | Appointed | 2025-08-13 |
| Raymond Kelleher | member of the PubCo Board | Appointed | 2025-08-13 |
| Bihua Chen | member of the PubCo Board | Appointed | 2025-08-13 |
| Praveen Tipirneni | member of the PubCo Board | Appointed | 2025-08-13 |
| Neil Kumar | member of the PubCo Board | Appointed | 2025-08-13 |
| Frank McCormick | member of the PubCo Board | Appointed | 2025-08-13 |
| Eli Wallace | member of the PubCo Board | Appointed | 2025-08-13 |
| Yong Ben | PubCo’s Chief Medical and Development Officer | Appointed | 2025-08-13 |
| Pedro Beltran | PubCo’s Chief Scientific Officer | Appointed | 2025-08-13 |
| Uneek Mehra | PubCo’s Chief Financial Officer (serving as principal financial officer and principal accounting officer) | Appointed | 2025-08-13 |
| Eli Wallace | PubCo’s Chief Executive Officer (serving as principal executive officer) | Appointed | 2025-08-13 |
Key facts
CIK
1869105
CUSIP
107924102
13F (30d)
65 filings
65 filers
Visit website
Investor relations